Committee for Advanced Therapies (CAT) expert meeting on scientific and regulatory considerations for adeno-associated viral vector (AVV)-based gene therapy

• Date:
  Wednesday, 06 September 2017
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

An increasing number of recombinant AAV-based gene therapy medicinal products have entered clinical development in various therapeutic areas, including ophthalmology, neurology, haematology, metabolic disorders and muscular disorders. During this expert meeting, the CAT discussed with invited experts various scientific aspects of recombinant AAVs such as clinical grade manufacturing, virus-host interactions in animals and humans, immunity, persistence, toxicity and clinical development.

Documents

Report from the CAT expert meeting - Scientific and regulatory considerations for adeno-associated viral vector (AAV)-based gene therapy

Reference Number: EMA/CAT/60852/2018